EVO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 22:00):

Stats
Dagens volum	226 635
Gjennomsnittsvolum	99 120.00
Markedsverdi	1.84B
EPS	$-0.120 ( 2023-11-08 )
Last Dividend	$0.0722 ( 2019-01-11 )
Next Dividend	$0 ( N/A )
P/E	-20.80
ATR14	$0.00700 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2018-10-22	Anderson Mark Monroe	Buy	100 000	Stock Option (right to buy)
2018-10-22	Anderson Mark Monroe	Buy	0
2018-08-13	Smith Scott Clifford	Buy	100 000	Stock Option (right to buy)
2018-08-13	Smith Scott Clifford	Buy	0
2018-08-13	Laffer Arthur B	Buy	100 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 13 transactions
Buy: 500 392 \| Sell: 1 057

Volum Korrelasjon

Lang: 0.00 (neutral)

Kort: -0.61 (weak negative)

Signal:(45.474) Neutral

Eaton Vance Ohio Korrelasjon

10 Mest positive korrelasjoner
SOJD	0.872
RYB	0.869
WPM	0.869
NEU	0.869
KBH	0.867
SAP	0.851
GLDM	0.85
SGOL	0.85
OUNZ	0.849
BAR	0.849

10 Mest negative korrelasjoner
DZZ	-0.856
EQNR	-0.84
GLL	-0.836
DGZ	-0.835
EBF	-0.829
DBMF	-0.817
RPM	-0.814
PKO	-0.814
PCQ	-0.814
KMLM	-0.809

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Eaton Vance Ohio Korrelasjon - Valuta/Råvare

0.24
( neutral )

-0.35
( neutral )

0.00
( neutral )

0.01
( neutral )

-0.71
( moderate negative )

-0.13
( neutral )

Eaton Vance Ohio Økonomi

Annual	2023
Omsetning:	$781.43M
Bruttogevinst:	$175.05M (22.40 %)
EPS:	$-0.470

FY	2023
Omsetning:	$781.43M
Bruttogevinst:	$175.05M (22.40 %)
EPS:	$-0.470

FY	2022
Omsetning:	$751.45M
Bruttogevinst:	$174.07M (23.16 %)
EPS:	$-0.990

FY	2021
Omsetning:	$618.03M
Bruttogevinst:	$151.54M (24.52 %)
EPS:	$0.650

Financial Reports:

No articles found.

Eaton Vance Ohio Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Eaton Vance Ohio Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 3.29 - low (9.42%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0561	2001-01-05
Last Dividend	$0.0722	2019-01-11
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	221	--
Total Paid Out	$14.33	--
Avg. Dividend % Per Year	0.00%	--
Score	3.48	--
Div. Sustainability Score	3.29
Div.Growth Potential Score	0
Div. Directional Score	1.593	--

Next Divdend (Est)
(2024-06-25)

$0 Estimate 0.00 %

Dividend Stability

0.16 Bad

Dividend Score

3.48

Pay Frequency

Monthly

Yearly Payout

Year	Amount	Yield
2001	$0	0.00%
2002	$0	0.00%
2003	$0	0.00%
2004	$1.008	24.50%
2005	$1.024	55.70%
2006	$0.704	34.50%
2007	$0.650	153.20%
2008	$0.738	177.80%
2009	$0.814	150.70%
2010	$0.966	61.90%
2011	$0.857	41.40%
2012	$0.832	54.40%
2013	$0.793	45.30%
2014	$0.732	28.90%
2015	$0.732	32.70%
2016	$0.570	25.20%
2017	$0.576	14.20%
2018	$0.495	6.05%
2019	$0.0722	0.71%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
MTR	Dividend Diamond	2023-10-30	Monthly	39	10.10%	8.50
PDI	Dividend Royal	2023-11-10	Monthly	13	7.86%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.111	1.500	-2.22	-3.33	[0 - 0.5]
returnOnAssetsTTM	-0.0367	1.200	-1.224	-1.469	[0 - 0.3]
returnOnEquityTTM	-0.0731	1.500	-1.923	-2.88	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.944	0.800	5.28	4.22	[1 - 3]
quickRatioTTM	1.740	0.800	4.47	3.58	[0.8 - 2.5]
cashRatioTTM	1.100	1.500	5.00	7.50	[0.2 - 2]
debtRatioTTM	0.272	-1.500	5.46	-8.19	[0 - 0.6]
interestCoverageTTM	-6.79	1.000	-3.63	-3.63	[3 - 30]
operatingCashFlowPerShareTTM	0.192	2.00	9.94	10.00	[0 - 30]
freeCashFlowPerShareTTM	-1.029	2.00	-0.514	-1.029	[0 - 20]
debtEquityRatioTTM	0.559	-1.500	7.76	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.226	1.000	9.57	9.57	[0.2 - 0.8]
operatingProfitMarginTTM	-0.0826	1.000	-3.65	-3.65	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0542	1.000	-0.810	-0.810	[0.2 - 2]
assetTurnoverTTM	0.330	0.800	-1.130	-0.904	[0.5 - 2]
Total Score				3.29

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-9.81	1.000	-1.092	0	[1 - 100]
returnOnEquityTTM	-0.0731	2.50	-1.236	-2.88	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.029	2.00	-0.343	-1.029	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.192	2.00	9.94	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0246	1.500	-3.17	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0447	1.000	-1.383	0	[0.1 - 0.5]
Total Score				-0.101

Eaton Vance Ohio

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.